Company profile: iTeos Therapeutics
1.1 - Company Overview
Company description
- Provider of immuno-oncology drug discovery and development focused on tumor immunology and the metabolism of the tumor microenvironment, delivering small molecule immunomodulators and antibody therapies for cancer. Portfolio includes EOS-448 (anti-TIGIT IgG1), Inupadenant (A2AR inhibitor), and EOS-984 (preclinical). Conducts clinical trials and advances monotherapy and combination therapy approaches across cancer indications.
Products and services
- Drug Development Pipeline: Develops immuno-oncology therapeutics across various cancer indications using monotherapy and combination therapy approaches, combination-therapy-capable
- EOS-448: Human IgG1 anti-TIGIT antibody engineered to inhibit TIGIT-mediated immunosuppression on CD8+ T cells, NK cells, and Tregs, enhancing anti-tumor immune activity
- Inupadenant: A2AR-specific agent inhibiting the ATP-adenosine pathway by targeting A2AR, the primary adenosine receptor on immune cells, to modulate immune responses in cancer
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to iTeos Therapeutics
Agenus
HQ: United States
Website
- Description: Provider of immunotherapies and vaccines for cancer and infectious diseases, advancing antibodies that activate antitumor immunity: botensilimab (CTLA-4; Phase 2 in melanoma, MSS colorectal and pancreatic cancers), balstilimab (PD-1; backbone for combinations), zalifrelimab (CTLA-4), AGEN2373 (CD137 agonist), AGEN1571 (ILT-2 antagonist), and an anti-ILT4 antagonist developed with pembrolizumab and chemotherapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Agenus company profile →
Tiziana Life Sciences
HQ: United Kingdom
Website
- Description: Provider of biotechnology therapies focused on discovery and development of novel molecules in oncology and immunology, including Intranasal Foralumab (anti-CD3 nasal immunotherapy for neuroinflammatory and neurodegenerative diseases), Anti IL-6R mAb (TZLS-501) to reduce inflammation in idiopathic pulmonary fibrosis and autoimmune diseases, and Milciclib, a CDK-targeting cancer therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tiziana Life Sciences company profile →
Exacis
HQ: United States
Website
- Description: Provider of development-stage immuno-oncology solutions, using mRNA-based cell reprogramming to create iPSC and mRNA-based gene editing to engineer iPSC, creating engineered NK and T cells designed to resist host immune rejection to harness the human immune system against cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exacis company profile →
Cangene
HQ: United States
Website
- Description: Provider of immune therapeutics through fully integrated development and manufacturing, with a solid track record of developing and commercializing plasma-derived products that address multiple therapeutic areas; first drug WinRho SDF has been commercially available since 1980.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cangene company profile →
Visterra
HQ: United States
Website
- Description: Provider of therapeutic and diagnostic products and R&D for infectious diseases, leveraging structure-based design informed by glycobiology and glycochemistry. Pipeline includes Sibeprenlimab (VIS649) for IgA nephropathy, VIS171 (modified IL-2) to activate Tregs, and VIS513 for dengue. Platforms: HIEROTOPE for epitope selection/design and ViSTAR Fc modifications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Visterra company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for iTeos Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to iTeos Therapeutics
2.2 - Growth funds investing in similar companies to iTeos Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for iTeos Therapeutics
4.2 - Public trading comparable groups for iTeos Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →